WeightWatchers gets into prescription weight loss business

Ozempic and Wegovy are different versions of the same drug, known as semaglutide. They’re both given as once-weekly injections. Ozempic is approved only to treat diabetes, although it has been increasingly prescribed for off-label use. Wegovy was approved in 2021 to treat obesity in adults, and late last year to treat the condition in adolescents 12 and older.

Both Ozempic and Wegovy can cause possible side effects, the company reports. They include possible thyroid cancer, pancreatitis, kidney and gallbladder problems. The most common side effects are nausea, vomiting, diarrhea, stomach pain and constipation. “This deal brings access to prescription drug solutions for weight loss to WW’s historical focus on behavior modification model,” wrote UBS analyst Michael Lasser. “This is a significant change in the business. While the deal could bring considerable upside, it also carries sizable risks.”

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

WeightWatchers gets into prescription weight loss businessWeightWatchers soared Tuesday after the company said it was getting into the prescription drug weight loss business with the acquisition of Sequence. There is always a pill for that 🙃🤣 Fantastic, more drug pushers!
출처: CTVNews - 🏆 1. / 99 더 많은 것을 읽으십시오 »

WeightWatchers gets into prescription weight loss business - Terrace StandardWeightWatchers soared Tuesday after the company said it was getting into the prescription drug weight loss business with the acquisition of Sequence.
출처: TerraceStandard - 🏆 24. / 68 더 많은 것을 읽으십시오 »

Market movers: Stocks seeing action on Tuesday - and whyA look at North American equities heading in both directions
출처: globeandmail - 🏆 5. / 92 더 많은 것을 읽으십시오 »